Ozempic Gastroparesis Settlement: Criteria Explained

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Targeted Risk Awareness

For decades, the domain of general health and science information has served as a foundational resource for public awareness, offering broad guidance on wellness, disease prevention, and medical advancements. Within this legacy context, audiences have been educated about common health risks and the importance of staying informed about emerging treatments and safety concerns. This heritage of accessible, neutral health communication now provides a critical framework for addressing more specific, evolving public health issues. As the landscape of pharmaceutical interventions expands, a new area of focus has emerged: the intersection of widely prescribed medications and unforeseen adverse effects. One such concern involves the use of glucagon-like peptide-1 receptor agonists, like Ozempic, and their potential association with delayed gastric emptying, a condition known as gastroparesis.

Understanding the Link Between Ozempic and Gastroparesis

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While effective for these indications, its use has been associated with gastrointestinal adverse reactions, including conditions such as gastroparesis, a disorder characterized by delayed gastric emptying without mechanical obstruction. Gastroparesis presents clinically with symptoms including nausea, vomiting, early satiety, postprandial fullness, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy or breath tests to confirm delayed emptying. The condition can lead to malnutrition, weight loss, and impaired quality of life. In the context of Ozempic, the drug's mechanism as a GLP-1 receptor agonist slows gastric emptying as part of its glucose-lowering effect, which can exacerbate or precipitate gastroparesis in susceptible individuals.

Clinical Evidence and Risk Data

Clinical trial data from the Ozempic prescribing information document a higher incidence of gastrointestinal adverse reactions in patients receiving the drug compared to placebo. In pooled placebo-controlled trials, gastrointestinal adverse reactions occurred in 15.3% of placebo patients, 32.7% of those on Ozempic 0.5 mg, and 36.4% of those on Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. Discontinuation due to gastrointestinal adverse reactions was higher in Ozempic-treated patients: 3.1% for the 0.5 mg dose and 3.8% for the 1 mg dose, compared to 0.4% for placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently with the 2 mg dose (34.0%) versus the 1 mg dose (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions reported at frequencies below 5% include dyspepsia (placebo 1.9%, Ozempic 0.5 mg 3.5%, Ozempic 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate a dose-dependent increase in gastrointestinal side effects, which may reflect the drug's impact on gastric motility.

Mechanism and Warning Adequacy

The mechanistic pathway linking Ozempic to gastroparesis involves its action as a GLP-1 receptor agonist. GLP-1 receptors are expressed in the gastrointestinal tract, and activation slows gastric emptying by inhibiting antral contractions and stimulating pyloric tone. This pharmacodynamic effect is intended to reduce postprandial glucose excursions but can become pathological in patients with pre-existing gastroparesis or those who develop severe delayed emptying. Chronic use may lead to sustained impairment of gastric motility, resulting in symptoms consistent with gastroparesis. Regarding risk considerations, the adequacy of warnings about Ozempic and gastroparesis is a key issue. The prescribing information lists gastrointestinal adverse reactions but does not explicitly mention gastroparesis as a specific warning or precaution. The label notes that Ozempic has not been studied in patients with a history of pancreatitis and advises considering other therapies in such patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, there is no dedicated warning about gastroparesis, which may leave patients and clinicians unaware of the potential for this serious complication. This gap in labeling could be relevant for settlement considerations, as affected patients may argue that the risks were not adequately communicated.

Settlement Criteria and Documentation

For patients who develop gastroparesis after Ozempic exposure, settlement-related considerations include documenting the timeline between drug initiation and symptom onset. The label indicates that gastrointestinal adverse reactions often occur during dose escalation, suggesting that harm may manifest within weeks to months of starting treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Patients should maintain records of prescription dates, dosage changes, and symptom progression to establish a causal link. Medical records confirming a diagnosis of gastroparesis through gastric emptying studies, along with exclusion of other causes, are essential for supporting claims. In summary, Ozempic is associated with a significantly increased risk of gastrointestinal adverse reactions, including symptoms consistent with gastroparesis, as evidenced by clinical trial data. The drug's mechanism of slowing gastric emptying provides a plausible pathway for this harm. The adequacy of warnings in the prescribing information is limited, as gastroparesis is not explicitly addressed. Patients affected by this condition should consider documenting their exposure and symptoms carefully for potential settlement or legal evaluation.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Ozempic and gastroparesis?

Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying as part of its mechanism. This can exacerbate or precipitate gastroparesis, a condition of delayed gastric emptying, in susceptible individuals. Clinical trials show a higher incidence of gastrointestinal adverse reactions in Ozempic users compared to placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

What are the settlement criteria for Ozempic-related gastroparesis?

Settlement criteria typically require documented Ozempic exposure, a confirmed diagnosis of gastroparesis via gastric emptying studies, and a timeline linking drug initiation to symptom onset. Patients should maintain records of prescriptions, dosage changes, and medical evaluations to support their claim.

Does the Ozempic label warn about gastroparesis?

The prescribing information lists gastrointestinal adverse reactions but does not explicitly mention gastroparesis as a specific warning or precaution. This lack of explicit warning may be relevant for legal claims regarding inadequate risk communication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Ozempic Prescribing Information (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.